STOCK TITAN

Intensity Therapeutics (INTS) grants 78,000 stock options to its CEO

(Neutral)
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Intensity Therapeutics, Inc. reported that President and CEO Lewis H. Bender received a grant of 78,000 stock options on July 16, 2026. The options carry an exercise price of $4.90 per share and expire on July 16, 2036. They vest in four equal annual installments beginning July 16, 2026, subject to his continued service, and represent an acquisition of derivative securities rather than a market purchase or sale of common stock.

Positive

  • None.

Negative

  • None.
Insider BENDER LEWIS H
Role President and CEO
Type Security Shares Price Value
Grant/Award Stock Option (right to buy Common Stock) F1 78,000 $0.00 $0.00
Holdings After Transaction: Stock Option (right to buy Common Stock) — 78,000 shares (Direct)
Footnotes (1)
  1. F1. This option will vest, subject to the individual's continued service with Intensity Therapeutics, Inc., in four, equal, annual installments, beginning on July 16, 2026.
Stock options granted 78,000 options Grant to President and CEO Lewis H. Bender on July 16, 2026
Exercise price $4.90 per share Exercise price for the granted stock options
Options owned after grant 78,000 options Total derivative securities beneficially owned after the reported transaction
Vesting schedule 4 annual installments Equal annual vesting installments beginning July 16, 2026
Option expiration date July 16, 2036 Expiration date of the granted stock options
Stock Option financial
"Security title: Stock Option (right to buy Common Stock)"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
exercise price financial
"conversion_or_exercise_price: 4.9000"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date: 2036-07-16"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
vest financial
"This option will vest, subject to the individual's continued service"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What insider transaction did INTS report for Lewis H. Bender?

Intensity Therapeutics reported that CEO Lewis H. Bender received a grant of 78,000 stock options on July 16, 2026. These options relate to common stock, are compensation-based, and do not represent an open-market purchase or sale of shares.

What is the exercise price of the new stock options granted at INTS?

The granted stock options have an exercise price of $4.90 per share. This is the price at which Lewis H. Bender may purchase Intensity Therapeutics common stock upon exercising the options before their expiration date.

How do the INTS stock options granted to the CEO vest?

The 78,000 stock options granted to the INTS CEO vest in four equal annual installments beginning on July 16, 2026. Vesting is explicitly conditioned on his continued service with Intensity Therapeutics, Inc. through each vesting date.

When do the INTS CEO’s newly granted stock options expire?

The newly granted stock options to the INTS CEO expire on July 16, 2036. After that date, any unexercised options will lapse, and the right to purchase common stock at the $4.90 exercise price will terminate.

Is the INTS CEO’s option grant reported under a Rule 10b5-1 trading plan?

The filing indicates that the Rule 10b5-1 checkbox is not marked for this transaction. This suggests the reported option grant was not identified as made pursuant to a pre-arranged Rule 10b5-1 trading plan.

How many derivative securities does the INTS CEO hold after this grant?

Following this reported grant, Lewis H. Bender holds 78,000 stock options as derivative securities. This figure reflects the total options reported as beneficially owned after the July 16, 2026 transaction.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
BENDER LEWIS H

(Last)(First)(Middle)
C/O INTENSITY THERAPEUTICS, INC.
1 ENTERPRISE DRIVE, SUITE 430

(Street)
SHELTON CONNECTICUT 06484

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
INTENSITY THERAPEUTICS, INC. [ INTS ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
President and CEO
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
07/16/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy Common Stock)$4.907/16/2026A78,00007/16/2026(1)07/16/2036Common Stock78,000$078,000D
Explanation of Responses:
1. This option will vest, subject to the individual's continued service with Intensity Therapeutics, Inc., in four, equal, annual installments, beginning on July 16, 2026.
Remarks:
/s/ Kostantinos Skordalos, Attorney-in-fact07/20/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)